Return to the catalog
KPV
NewIn Stock10mg vial

KPV

Three-amino-acid peptide studied for inflammation in the gut, skin, and immune cells.

For Research Use Only

Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.

1–4 vialsR 500.00
5+ vials — save 30%R 350.00 each

The lower price is applied automatically once your cart holds 5 or more of this vial.

Bacteriostatic water included

99%+ Purity
Extensively Researched
1

About this peptide

KPV is a targeted tripeptide derived from the terminal three amino acids of alpha-MSH, a naturally occurring signalling hormone. In laboratory research, KPV is widely studied for its ability to calm inflammatory cascades directly at the cellular level—particularly in the gut lining, skin tissue, and active immune cells. By dampening pro-inflammatory signals and helping restore tissue balance, it has become a primary focus in gut health and barrier-repair models. Crucially, unlike the parent alpha-MSH molecule, KPV carries out these anti-inflammatory effects without stimulating pigment production or skin darkening.

Why researchers reach for KPV

Mucosal inflammation

Studied in colitis and IBD rodent models.

Cytokine suppression

Reduces NF-κB driven cytokine output in vitro.

No pigmentation effect

Retains anti-inflammatory core without melanocortin-1 activity.

Key features

  • ≥99% HPLC purity
  • α-MSH C-terminal tripeptide
  • Mass-spec verified
  • Cold-chain dispatch

How it works

NF-κB inhibition

Suppresses TNF-α induced NF-κB activation.

Epithelial uptake

Enters cells via PepT1 transporter in research models.

Th17 modulation

Alters IL-17 and IL-1β expression in intestinal studies.

Research dosage guidelines

Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.

RangeReported doseNote
Typical reconstitution2 mL bacteriostatic waterYields 5 mg/mL (5000 mcg/mL)
Reported research range200–500 mcg/dayReference only

Tracking this compound? Registered researchers can log active KPV protocols in their private Research Log.

Timing in research protocols

No human pharmacokinetic study; rodent data suggest a short window of action.

  • Secondary sources citing rodent data place peak plasma levels roughly 45–90 minutes after subcutaneous administration, with clearance in 4–6 hours.
  • That short profile is consistent with rapid enzymatic degradation of an unmodified tripeptide.
  • Primary mechanistic literature is in vitro and in rodent colitis models, with no human dosing schedule.
  • No evidence-based time of day or meal relationship exists.

Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.

Technical specifications

Sequence
Lys-Pro-Val
Molecular weight
342.4 g/mol
Purity
≥99% (HPLC)
Form
Lyophilized powder
Vial size
10 mg
Storage (lyophilised vial)
Cool, dry and protected from light
Storage (after reconstitution)
2–8°C

Published research

Peer-reviewed literature on KPV. Links open in a new tab.

Research use notice

Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.

#anti-inflammatory#gut#MSH-fragment

Cart (0)

Your cart is empty